Synapse - Works

Results (4760)

Single-agent ibrutinib demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, phase 2 study

Meeting Abstract

Noy, A.; de Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C.; Morschhauser, F.; Collins, G. P.; Ma, S.; Coleman, M.; Peles, S.; more...
Blood (2016)

Fulltext@MSK | Save

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma

Meeting Abstract

Mondello, P.; Derenzini, E.; Asgari, Z.; Philip, J.; Brea, E. J.; Seshan, V. E.; Hendrickson, R.; de Stanchina, E.; Scheinberg, D. A.; Younes, A.
Blood (2016)

Fulltext@MSK | Save

Predictive value of mutation analysis in the diagnostic approach to patients with unexplained cytopenia

Meeting Abstract

Malcovati, L.; Gallì, A.; Travaglino, E.; Ambaglio, I.; Rizzo, E.; Molteni, E.; Elena, C.; Catricalà, S.; Bono, E.; Bianchessi, A.; more...
Blood (2016)

Fulltext@MSK | Save

ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): Final results of the SWOG/Alliance/ECOG S0535 trial

Meeting Abstract

Lancet, J. E.; Moseley, A.; Komrokji, R. S.; Coutre, S. E.; DeAngelo, D. J.; Tallman, M. S.; Litzow, M.; Othus, M.; Appelbaum, F. R.
Blood (2016)

Fulltext@MSK | Save

Organ biomarker responses in patients with light chain amyloidosis treated with NEOD001 are independent of previous hematologic response

Meeting Abstract

Liedtke, M.; Comenzo, R. L.; Landau, H.; Sanchorawala, V.; Weiss, B. M.; Zonder, J. A.; Walling, J.; Kinney, G. G.; Koller, M.; Schenk, D. B.; more...
Blood (2016)

Fulltext@MSK | Save

Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health

Meeting Abstract

List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K. L.; Nardelli, L. A.; Maciejewski, J. P.; Altman, J. K.; Cheema, P.; Claxton, D. F.; more...
Blood (2016)

Fulltext@MSK | Save

Genetic alterations predict outcomes in patients with myelodysplastic syndrome receiving allogeneic hematopoietic stem cell transplantation

Meeting Abstract

Lindsley, R. C.; Saber, W.; Mar, B. G.; Redd, R. A.; Haagenson, M. D.; Grauman, P. V.; Spellman, S. R.; Lee, S. J.; Wang, T.; Verneris, M. R.; more...
Blood (2016)

Fulltext@MSK | Save

Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity

Meeting Abstract

Kunimoto, H.; Meydan, C.; Nazir, A.; Shank, K.; Maher, R.; Rapaport, F.; Pronier, E.; Melnick, A.; Levine, R. L.; Shih, A. H.
Blood (2016)

Fulltext@MSK | Save

Synthetic lethal interactions of MDS-associated spliceosomal gene mutations identifies the basis for their mutual exclusivity

Meeting Abstract

Lee, S. C. W.; Dilai, K.; Obeng, E. A.; Kim, E.; Micol, J. B.; Yoshimi, A.; Willekens, C.; Inoue, D.; Saada, V.; Cho, H.; more...
Blood (2016)

Fulltext@MSK | Save

Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy

Meeting Abstract

Hughes, T. P.; Goh, Y. T.; Ottmann, O. G.; Minami, H.; Rea, D.; Lang, F.; Mauro, M. J.; DeAngelo, D. J.; Talpaz, M.; Hochhaus, A.; more...
Blood (2016)

Fulltext@MSK | Save